Antimicrobial resistance is one of the major problems in current practical medicine. The
spread of genes coding for resistance determinants among bacteria challenges the use of …

The spread of metallo-β-lactamase (MBL)-producing Enterobacterales worldwide without
the simultaneous increase in active antibiotics makes these organisms an urgent public …

Abstract Metallo-β-lactamases (MBLs) are zinc-dependent hydrolases that inactivate
virtually all β-lactam antibiotics. The expression of MBLs by Gram-negative bacteria severely …

Understanding the evolution of metallo-β-lactamases (MBLs) is fundamental to deciphering
the mechanistic basis of resistance to carbapenems in pathogenic and opportunistic …

New Delhi metallo-β-lactamase (NDM) grants resistance to a broad spectrum of β-lactam
antibiotics, including last-resort carbapenems, and is emerging as a global antibiotic …

Carbapenems are last-resort antibiotics for treating bacterial infections. The widespread
acquisition of metallo-β-lactamases, such as VIM-2, contributes to the emergence of …

ABSTRACT Metallo-β-lactamases (MBLs) are a growing clinical threat because they
inactivate nearly all β-lactam-containing antibiotics, and there are no clinically available …

To identify novel inhibitors of the carbapenemase New Delhi metallo-β-lactamase (NDM) as
possible therapeutic compounds, we conducted a high-throughput screen of a 43,358 …

To probe the mechanism of inhibition of several previously-published metallo-β-lactamase
(MBL) inhibitors for the clinically-important MBL Verona integron-encoded metallo-β …

The fungal natural product aspergillomarasmine A (AMA) has been identified as a
noncompetitive inhibitor of New Delhi metallo‐β‐lactamase‐1 (NDM‐1) that inhibits by …